SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys sharp selloff after its Q3 report dominates discussion: traders point to softer-than-expected merchandise volume and slower projected gross-profit growth, despite solid profitability and cash generation. Bears say the high valuation left little room for disappointment, while bulls view the reaction as excessive given continued growth.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstarts Q3 results have traders debating strong revenue growth and a return to profitability against cautious, lower guidance, which many blame for the selloff. Bulls see improving loan volume and margins as evidence the business is gaining traction, while bears focus on interest-rate, credit-risk and funding concerns.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Reports that nonprofit Usona may have filed an FDA application for psilocybin in major depressive disorder triggered a sharp selloff and concerns about competition and which company could reach the market first. Traders debate the threat, noting Compass is targeting treatment-resistant depression and has commercial infrastructure, while questioning how confirmed Usonas filing is and watching for Compasss own NDA completion.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins third-quarter results are drawing attention, with traders welcoming stronger profitability and a new share-repurchase program while debating the revenue shortfall and weak same-store sales. The reaction is split between optimism about margins and expansion and frustration that the stock remains range-bound, with some also noting the lack of relisting guidance.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehrs fiscal Q1 results beat expectations, with record revenue, strong bookings and a higher fiscal-year outlook supporting optimism about AI-chip burn-in testing demand. Traders are cheering the growth but debating the stocks rich valuation and whether the gains can hold amid market weakness and AEHRs volatility.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Backblazes quarterly results and raised full-year outlook are driving attention, with traders focused on accelerating B2 cloud-storage growth and its potential role in AI infrastructure. The reaction is divided: some see strong execution and improving cash generation, while others flag weaker retention, declining legacy backup revenue and the risk of a sell-the-news pullback.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Michael Burrys disclosed Fiserv position is drawing attention, with bullish traders framing the payments company as a contrarian value play and pointing to potential valuation read-through from reported interest in Global Payments. Others remain skeptical, citing Fiservs guidance cuts and unresolved execution concerns.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals quarterly results are drawing attention, with traders highlighting strong Rezdiffra growth and profitability. Reactions are mixed: some see the commercial momentum as encouraging, while others are concerned about the lack of guidance and spending, and frustrated that the shares faded after an initial rise.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong quarterly results and raised outlook were met with a selloff, as traders focused on the stocks rich valuation and slower growth in total contract value as possible signs that expectations are too high. Bulls point to rapid commercial AI adoption and stronger guidance, while others question whether bookings can sustain the growth priced into the shares.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is drawing attention ahead of its quarterly report, as traders weigh whether its AI and data-center outlook can counter concerns sparked by Intels weak forecast and the broader semiconductor selloff. Some see the pullback as setting up a rebound on strong guidance, while others fear that even a beat may not prevent more selling amid valuation and sector-wide concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop

Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock DropPR...

Aquestive Therapeutics Resubmits NDA For Anaphylm Sublingual Film

(RTTNews) - Aquestive Therapeutics (AQST) announced that it has resubmitted its New Drug Application to the FDA for Anaphylm sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. The company said the resubmission is supported by positive topline h...

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics Q2 Earnings Call Highlights...

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.read more...

Guardian Pharmacy Services (GRDN) Q2 Earnings and Revenues Top Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +11.54% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?

Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aquestive Therapeutics Q1 Earnings Call Highlights

Aquestive Therapeutics Q1 Earnings Call Highlights...

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Why Did AQST Stock Jump 35% Today?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The FDA’s concerns were limited to packaging, labeling, and administration issues, the company said.</li><li>Aquestive has already modified the pouch design, updated instructions for use, and revised labelling.</li><li>The firm is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K last year.</li></ul>Shares of Aquestive Therapeutics (AQST) surged more than 35% on Monday morning, after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.A CRL indicates that while a drug has not been approved in its current form, it allows the sponsor to address the issues raised by the FDA and seek re-approval.<h2 class="st-heading-2">FDA’s Concerns</h2>The FDA’s concerns were limited to packaging, labeling, and administration issues identified in a human factors validation study. The FDA noted that some users had difficulty opening the pouch and correctly placing the film, which could pose safety risks during emergency situations. The agency did not raise questions about the drug’s comparability data or manufacturing processes, the company said.To address the feedback, Aquestive has modified the pouch design, updated instructions for use, and revised labeling. The company plans to conduct a new human factors study alongside a single pharmacokinetics (PK) study requested by the FDA. No additional trials are required.Based on the initial review, Aquestive expects to resubmit the application as early as the third quarter of 2026 and will seek a rapid review.<h2 class="st-heading-2">Europe Update</h2>Aquestive is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K. in 2025. The European Medicines Agency indicated that no additional clinical trials are required, with submissions in Europe and Canada expected in the second half of 2026. The company also anticipates feedback from the U.K.’s MHRA in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a session earlier, amid ‘high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_c092cd62f6.webp" alt="AQST.jpg">One user brushed off concerns about the CRL, noting there were no key issues.<stembedurl>https://stocktwits.com/BigGainTom/message/643649716</stembedurl>While the stock has gained nearly 35% over the past year, its year-to-date losses are around 40%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/precious-metals-extend-historic-rout/cZbg8EJR4kf">Gold, Silver Continue To Decline – Analysts Warn Of Crowded Trades As Precious Metals Extend ‘Historic Rout’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

iShares Micro-Cap ETF

iShares Russell 2000 Value ETF

iShares Russell 2000 Growth ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$3.77
Prev Close	$3.89
Open	$3.92
Dividend Yield	0.00%
50-Day Moving Average	$4.64
Beta	1.33
Avg. Volume	2.12M
PE Ratio	-5.80

52-Week High	$6.85
52-Week Low	$2.93
Market Capitalization	$473.18M
EPS (Annual)	-$0.7836
Price to Book	-8.36
Revenue Per Employee	$303,027.21

Feed

News

Sentiment

Earnings

Fundamentals

Info

AQST Fundamentals